Zinc Transporter 8 Antibody

Overview

Zinc transporter 8 antibody (ZnT8A) is an autoantibody targeting the zinc transporter 8 protein (SLC30A8) on insulin secretory granules in pancreatic beta cells. It appears in the autoimmune destruction of beta cells during type 1 diabetes pathogenesis, typically after GAD65 and IA-2 autoantibodies. Presence of ZnT8A increases type 1 diabetes risk prediction, particularly when combined with other islet autoantibodies, while absence lowers risk. Clinically, ZnT8A testing improves early diagnosis and risk stratification for type 1 diabetes in relatives of affected individuals and population screening.

Clinical Use Cases

  • Prediction of type 1 diabetes in first-degree relatives of patients.
  • Confirmation of autoimmune type 1 diabetes etiology in atypical presentations.
  • Population screening for type 1 diabetes risk (e.g., TEDDY study).
  • Staging presymptomatic type 1 diabetes (TrialNet screening).
  • Differentiation from type 2 diabetes or monogenic diabetes.

Specimen Types

  • Serum.
  • Plasma (EDTA preferred).

Measurement Methods

  • Radioimmunoassay (RIA).
  • Enzyme-linked immunosorbent assay (ELISA).
  • Electrochemiluminescence immunoassay.
  • Bridging immunoassay formats.

Test Preparation and Influencing Factors

  • No fasting required.
  • Sample stability good at -20°C; avoid repeated freeze-thaw cycles.
  • Age-dependent prevalence; highest sensitivity in youth-onset diabetes.
  • Rare cross-reactivity with other zinc transporters.
  • Immunosuppressive therapy may lower titers.

Synonyms

  • ZnT8 autoantibodies.
  • SLC30A8 autoantibodies.
  • Zinc transporter 8A.

Further Reading